AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18665934 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy only (control group, n = 179)
Number of subjects: 347
Study 17591649 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating energy protocol (protocol A: 100 J, 150 J, 200 J, 200 J)
Number of subjects: 380
Study 17591649 — intervention group
Group type: COMPARATOR
Intervention: Non-escalating energy protocol (protocol B: 200 J, 200 J, 200 J)
Number of subjects: 380
Study 17591649 — intervention group
Group type: COMPARATOR
Intervention: Non-escalating energy protocol (protocol B)
Number of subjects: 380
Study 17591649 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating energy protocol (protocol A)
Number of subjects: 380
Study 15219580 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 17
Study 15219580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11276273 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (1,000 to 2,000 mg/d)
Number of subjects: 335
Study 11276273 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (100 to 150 mg/d)
Number of subjects: 335
Study 9137259 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin, tobramycin, and amphotericin (PTA)
Number of subjects: 310
Study 9137259 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin, ciprofloxin, amphotericin (PCA)
Number of subjects: 310
Study 9137259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carrier only)
Number of subjects: 310
Study 8193093 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 24
Study 8193093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3605397 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of ethanol
Number of subjects: 60
Study 3605397 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 ml/kg of ethanol
Number of subjects: 60
Study 3605397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1095282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol, 16 mg
Number of subjects: 16
Study 1095282 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 8 mg
Number of subjects: 16
Study 1095282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolamolol
Number of subjects: 16
Study 1095282 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 16
Study 31339100 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSAFE (physiotherapy programme for fall prevention)
Number of subjects: 474
Study 30425466 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 64
Study 30425466 — intervention group
Group type: COMPARATOR
Intervention: Control (no current given)
Number of subjects: 64
Study 27129465 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced HIV test promotion video
Number of subjects: 721
Study 27129465 — intervention group
Group type: COMPARATOR
Intervention: Health marketing HIV test promotion video
Number of subjects: 721
Study 24733445 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsion adapter
Number of subjects: 10
Study 24733445 — intervention group
Group type: COMPARATOR
Intervention: Rigid adapter
Number of subjects: 10
Study 22850220 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled syringes
Number of subjects: 48
Study 22850220 — intervention group
Group type: COMPARATOR
Intervention: Preparing infusions de novo from ampoules
Number of subjects: 48
Study 22850220 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusions prepared by pharmacy and industry
Number of subjects: 48
Study 19628371 — intervention group
Group type: EXPERIMENTAL
Intervention: Type A yogurt (mainly Lactobacillus plantarum SN35N)
Number of subjects: 68
Study 19628371 — intervention group
Group type: EXPERIMENTAL
Intervention: Type B yogurt (mainly Lactobacillus plantarum SN13T)
Number of subjects: 68
Study 19628371 — intervention group
Group type: COMPARATOR
Intervention: Type C yogurt (mainly Lactococcus lactis A6 and Streptococcus thermophilus 510)
Number of subjects: 68
Study 17089403 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 150
Study 17089403 — intervention group
Group type: COMPARATOR
Intervention: Entacapone
Number of subjects: 150
Study 15589470 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus and steroids
Number of subjects: 121
Study 15589470 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin A, steroids, azathioprine, and ATG
Number of subjects: 121
Study 12405554 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) of 5 mg of LY 156735
Number of subjects: 8
Study 12405554 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (LD) of 0.5 mg of LY 156735
Number of subjects: 8
Study 12405554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 10442206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol sustained release capsules with food intake
Number of subjects: 24
Study 10442206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol sustained release capsules without food intake
Number of subjects: 24
Study 10442206 — intervention group
Group type: COMPARATOR
Intervention: Instant release formulation
Number of subjects: 24
Study 10442206 — intervention group
Group type: COMPARATOR
Intervention: Sustained release tablet (reference substance)
Number of subjects: 24
Study 8590851 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of rhG-CSF post chemotherapy with CHOP regimen
Number of subjects: 40
Study 8590851 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of rhG-CSF post chemotherapy with ProMACE/CytaBOM regimen
Number of subjects: 40
Study 8590851 — intervention group
Group type: COMPARATOR
Intervention: Previous study without rhG-CSF administration
Number of subjects: 40
Study 2609718 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (5 mg)
Number of subjects: 10
Study 2609718 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (2 mg)
Number of subjects: 10
Study 2609718 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine + Propranolol (2 mg + 5 mg)
Number of subjects: 10
Study 991149 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC alone
Number of subjects: 270
Study 991149 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC, CCNU, and vincristine
Number of subjects: 270
Study 991149 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC, BCNU, and vincristine
Number of subjects: 270
Study 991149 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC, BCNU, and hydroxyurea
Number of subjects: 270
Study 991149 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of agents including DTIC
Number of subjects: 270
Study 991149 — intervention group
Group type: COMPARATOR
Intervention: Responders vs nonresponders
Number of subjects: 270
Study 991149 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC, BCNU, and vincristine; DTIC, CCNU, and vincristine
Number of subjects: 270
Study 991149 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without brain or liver metastasis
Number of subjects: 270
Study 991149 — intervention group
Group type: COMPARATOR
Intervention: Men vs women
Number of subjects: 270
Study 991149 — intervention group
Group type: COMPARATOR
Intervention: Site of primary lesion
Number of subjects: 270
Study 31192538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pola Office (pH = 2.0)
Number of subjects: 28
Study 31192538 — intervention group
Group type: COMPARATOR
Intervention: Pola Office Plus (pH = 7.0)
Number of subjects: 28
Study 31192538 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 28
Study 25501356 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CWMT (45 min/session)
Number of subjects: 38
Study 25501356 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened CWMT (15 min/session)
Number of subjects: 38
Study 25501356 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 38
Study 25380538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobi-C cervical artificial disc (TDR)
Number of subjects: 330
Study 25380538 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 330
Study 24536060 — intervention group
Group type: EXPERIMENTAL
Intervention: Figitumumab plus docetaxel/prednisone (Arm A)
Number of subjects: 204
Study 24536060 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel/prednisone alone (Arm B1)
Number of subjects: 204
Study 24536060 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to Figitumumab plus docetaxel/prednisone (Arm B2)
Number of subjects: 204
Study 23035175 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE527 vaccine (10^11 CFU, two doses 21 days apart)
Number of subjects: 70
Study 23035175 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE527 vaccine
Number of subjects: 70
Study 19577029 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made orthosis
Number of subjects: 23
Study 19577029 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial orthosis
Number of subjects: 23
Study 19577029 — intervention group
Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 23
Study 17244104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (administered intravenously)
Number of subjects: 0
Study 17244104 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (administered intravenously)
Number of subjects: 0
Study 17244104 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (administered intravenously)
Number of subjects: 0
Study 17244104 — intervention group
Group type: COMPARATOR
Intervention: Other agents
Number of subjects: 0
Study 15219645 — intervention group
Group type: EXPERIMENTAL
Intervention: Galanin (4 x 50 microg administered hourly)
Number of subjects: 10
Study 15219645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15219645 — intervention group
Group type: EXPERIMENTAL
Intervention: Galanin
Number of subjects: 10
Study 15203948 — intervention group
Group type: EXPERIMENTAL
Intervention: WalkSafe Program (intervention schools)
Number of subjects: 2300
Study 11352392 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent
Number of subjects: 58
Study 11352392 — intervention group
Group type: COMPARATOR
Intervention: Visual examination
Number of subjects: 58
Study 11352392 — intervention group
Group type: COMPARATOR
Intervention: Radiographic examination
Number of subjects: 58
Study 9142797 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission LDH levels in patients with disseminated histoplasmosis
Number of subjects: 45
Study 9142797 — intervention group
Group type: COMPARATOR
Intervention: Admission LDH levels in control group (patients with advanced AIDS)
Number of subjects: 45
Study 8433725 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 395
Study 8433725 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tissue plasminogen activator (t‐PA)
Number of subjects: 395
Study 8433725 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PTCA
Number of subjects: 395
Study 8433725 — intervention group
Group type: COMPARATOR
Intervention: Intravenous t‐PA
Number of subjects: 395
Study 3315193 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide and lorazepam (M+L)
Number of subjects: 66
Study 3315193 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine and lorazepam (P+L)
Number of subjects: 66
Study 29516595 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating pad applied on the patient's sacrum during the urodynamic study
Number of subjects: 74
Study 28025924 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated CMR recruitment script
Number of subjects: 105701
Study 28025924 — intervention group
Group type: COMPARATOR
Intervention: Original CMR recruitment script
Number of subjects: 105701
Study 28025924 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of chronic medications
Number of subjects: 105701
Study 28025924 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of disease conditions
Number of subjects: 105701
Study 28025924 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous involvement in the MTMP
Number of subjects: 105701
Study 26178724 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index dietary advice
Number of subjects: 566
Study 26178724 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating advice
Number of subjects: 566
Study 24156746 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 70
Study 24156746 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 70
Study 24156746 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 70
Study 21519043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (placebo-controlled trial)
Number of subjects: 315
Study 21519043 — intervention group
Group type: EXPERIMENTAL
Intervention: ISAS
Number of subjects: 315
Study 21519043 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect sizes of 0.48 detected in several trials
Number of subjects: 315
Study 21519043 — intervention group
Group type: EXPERIMENTAL
Intervention: ISAS scores
Number of subjects: 315
Study 18326619 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel galactooligosaccharide (0, 3.6, or 7 g/d)
Number of subjects: 59
Study 18326619 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel galactooligosaccharide (7 g/d)
Number of subjects: 59
Study 18326619 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel galactooligosaccharide (0, 3.6, and 7 g/d)
Number of subjects: 59
Study 16552819 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha treatment
Number of subjects: 38
Study 16552819 — intervention group
Group type: COMPARATOR
Intervention: Control (no IFN-alpha treatment)
Number of subjects: 38
Study 12666702 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing with hand instruments and application of EMD
Number of subjects: 16
Study 12666702 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling with an ultrasonic instrument and application of EMD
Number of subjects: 16
Study 12666702 — intervention group
Group type: COMPARATOR
Intervention: Scaling with an ultrasonic instrument alone
Number of subjects: 16
Study 11009277 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol administered beginning 4 weeks before PTCA
Number of subjects: 101
Study 11009277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probucol)
Number of subjects: 101
Study 8775577 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal lavages (NAL) performed on amateur runners after the marathon race.
Number of subjects: 60
Study 8775577 — intervention group
Group type: COMPARATOR
Intervention: Nasal lavages (NAL) performed on healthy sedentary subjects (control group).
Number of subjects: 60
Study 1594169 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg for 7 days)
Number of subjects: 12
Study 1594169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 7 days)
Number of subjects: 12
Study 1594169 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 12
Study 1594169 — intervention group
Group type: COMPARATOR
Intervention: Atenolol and Placebo
Number of subjects: 12
Study 3882181 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg twice daily
Number of subjects: 0
Study 3882181 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg twice daily
Number of subjects: 0
Study 30367958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic formula (Ketonformula®) containing 20g of MCTs
Number of subjects: 20
Study 30367958 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric placebo formula without MCTs
Number of subjects: 20
Study 28475703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibinetide 1 mg/day
Number of subjects: 64
Study 28475703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibinetide 4 mg/day
Number of subjects: 64
Study 28475703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibinetide 8 mg/day
Number of subjects: 64
Study 28475703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 25512031 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg) added to bupivacaine (0.25% solution with adrenaline)
Number of subjects: 48
Study 25512031 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (0.25% solution with adrenaline) alone
Number of subjects: 48
Study 23774272 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dairy food intake
Number of subjects: 180
Study 23774272 — intervention group
Group type: COMPARATOR
Intervention: No change in dairy food intake
Number of subjects: 180
Study 23774272 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased dairy food intake
Number of subjects: 180
Study 22585373 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole nitrate oral disintegrating tablets (specific formulation details: magnesium stearate as lubricant, hydrophobic Aerosil R972 as glidant, low urea content, mannitol/microcrystalline cellulose ratio 2:1, and 9% Plasdone XL100 as superdisintegrant)
Number of subjects: 0
Study 22585373 — intervention group
Group type: COMPARATOR
Intervention: Physical blend of miconazole nitrate
Number of subjects: 0
Study 19425222 — intervention group
Group type: EXPERIMENTAL
Intervention: continued cART (n=48)
Number of subjects: 145
Study 19425222 — intervention group
Group type: COMPARATOR
Intervention: interrupted cART (n=97)
Number of subjects: 145
Study 17689635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise in systolic blood pressure over 30 mm Hg
Number of subjects: 5167
Study 17689635 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise in diastolic blood pressure over 15 mm Hg
Number of subjects: 5167
Study 17689635 — intervention group
Group type: EXPERIMENTAL
Intervention: Women experiencing early preterm birth
Number of subjects: 5167
Study 17689635 — intervention group
Group type: EXPERIMENTAL
Intervention: Women experiencing late preterm birth
Number of subjects: 5167
Study 15066949 — intervention group
Group type: COMPARATOR
Intervention: Dietary modification only
Number of subjects: 82
Study 15066949 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus a supervised structured exercise program
Number of subjects: 82
Study 15066949 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing exercise program
Number of subjects: 82
Study 11844850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine with S. aureus type 5 and 8 capsular polysaccharides conjugated to nontoxic recombinant Pseudomonas aeruginosa exotoxin A
Number of subjects: 1804
Study 11844850 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 1804
Study 10549094 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. application of FXIII concentrate
Number of subjects: 28
Study 10549094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8527465 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training programs (active and mental)
Number of subjects: 96
Study 2155747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 14
Study 2155747 — intervention group
Group type: COMPARATOR
Intervention: Trimetaphan camsylate
Number of subjects: 14
Study 6966069 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomized patients
Number of subjects: 17
Study 6966069 — intervention group
Group type: COMPARATOR
Intervention: Non-splenectomized patients
Number of subjects: 17
Study 6966069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17
Study 6136100 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam
Number of subjects: 0
Study 6136100 — intervention group
Group type: COMPARATOR
Intervention: Flunitrazepam
Number of subjects: 0
Study 6136100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31352621 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial receptivity array (ERA) test in Euploid‐ET
Number of subjects: 24
Study 31352621 — intervention group
Group type: COMPARATOR
Intervention: Euploid‐ET control group
Number of subjects: 24
Study 31352621 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial receptivity array (ERA) test in Donor‐ET
Number of subjects: 24
Study 31352621 — intervention group
Group type: COMPARATOR
Intervention: Donor‐ET control group
Number of subjects: 24
Study 30036871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and cognitive training for 6 consecutive weeks
Number of subjects: 100
Study 30036871 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 26781281 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (1.6 g per day)
Number of subjects: 120
Study 26781281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25484023 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal n-3 PUFA supplementation during pregnancy
Number of subjects: 70
Study 25484023 — intervention group
Group type: COMPARATOR
Intervention: Control group (no n-3 PUFA supplementation)
Number of subjects: 70
Study 22658255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 27
Study 22658255 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 27
Study 20384650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone 400 mg bid
Number of subjects: 504
Study 20384650 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone 600 mg qd for 28 days then 200 mg qd
Number of subjects: 504
Study 18715950 — intervention group
Group type: EXPERIMENTAL
Intervention: Motexafin gadolinium (MGd) at doses of 1.7 to 9.2 mg/kg daily prior to radiation therapy for 6 weeks
Number of subjects: 44
Study 18715950 — intervention group
Group type: EXPERIMENTAL
Intervention: Motexafin gadolinium (MGd) administered as a 5-min intravenous bolus 2-5 h prior to standard radiation therapy
Number of subjects: 44
Study 18715950 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiation therapy administered to 54 Gy in 30 once-daily fractions
Number of subjects: 44
Study 14975200 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT plus fluoxetine
Number of subjects: 123
Study 14975200 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 123